Sublingual immunotherapy not effective in house dust mite-allergic children in primary care

Cindy M A de Bot, Heleen Moed, Marjolein Y Berger, Esther Röder, Wim C J Hop, Hans de Groot, Johan C de Jongste, Roy Gerth van Wijk, Patrick J E Bindels, Johannes C van der Wouden

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND: Sublingual immunotherapy (SLIT) as a therapy for the treatment of allergic rhinitis in children might be acceptable as an alternative for subcutaneous immunotherapy. However, the efficacy of SLIT with house dust mite extract is not well established.

OBJECTIVE: To investigate whether SLIT in house dust mite-allergic children recruited in primary care is effective and safe.

METHODS: Children aged 6-18 years (n = 251) recruited in primary care with a house dust mite-induced allergic rhinitis received either SLIT or placebo for 2 years. Symptoms and medication use were assessed throughout the study. Primary outcome parameter was the mean total nose symptom score (scales 0-12) during the autumn of the second treatment year. Safety was assessed by recording any adverse event.

RESULTS: Overall, the mean nose symptom score ± s.d. after 2 years of treatment showed no significant effect of SLIT (symptom score intervention group 2.26 ± 1.84 vs. placebo group, 2.02 ± 1.67; p = 0.08). There were no significant differences in secondary outcomes, nor in subgroup analyses. The number of patients reporting adverse events was comparable between both groups.

CONCLUSIONS: Sublingual immunotherapy with house dust mite allergen was not better than placebo in reducing rhinitis symptoms in house dust mite-allergic children in primary care. SLIT as administered in this study can be considered safe.

Original languageEnglish
Pages (from-to)150-8
Number of pages9
JournalPediatric and Allergy Immunology
Volume23
Issue number2
DOIs
Publication statusPublished - Mar 2012

Cite this

de Bot, Cindy M A ; Moed, Heleen ; Berger, Marjolein Y ; Röder, Esther ; Hop, Wim C J ; de Groot, Hans ; de Jongste, Johan C ; van Wijk, Roy Gerth ; Bindels, Patrick J E ; van der Wouden, Johannes C. / Sublingual immunotherapy not effective in house dust mite-allergic children in primary care. In: Pediatric and Allergy Immunology. 2012 ; Vol. 23, No. 2. pp. 150-8.
@article{2000b64f7fb74c528f099f7b75c2982e,
title = "Sublingual immunotherapy not effective in house dust mite-allergic children in primary care",
abstract = "BACKGROUND: Sublingual immunotherapy (SLIT) as a therapy for the treatment of allergic rhinitis in children might be acceptable as an alternative for subcutaneous immunotherapy. However, the efficacy of SLIT with house dust mite extract is not well established.OBJECTIVE: To investigate whether SLIT in house dust mite-allergic children recruited in primary care is effective and safe.METHODS: Children aged 6-18 years (n = 251) recruited in primary care with a house dust mite-induced allergic rhinitis received either SLIT or placebo for 2 years. Symptoms and medication use were assessed throughout the study. Primary outcome parameter was the mean total nose symptom score (scales 0-12) during the autumn of the second treatment year. Safety was assessed by recording any adverse event.RESULTS: Overall, the mean nose symptom score ± s.d. after 2 years of treatment showed no significant effect of SLIT (symptom score intervention group 2.26 ± 1.84 vs. placebo group, 2.02 ± 1.67; p = 0.08). There were no significant differences in secondary outcomes, nor in subgroup analyses. The number of patients reporting adverse events was comparable between both groups.CONCLUSIONS: Sublingual immunotherapy with house dust mite allergen was not better than placebo in reducing rhinitis symptoms in house dust mite-allergic children in primary care. SLIT as administered in this study can be considered safe.",
keywords = "Administration, Sublingual, Adolescent, Animals, Antigens, Dermatophagoides/administration & dosage, Child, Desensitization, Immunologic/methods, Double-Blind Method, Female, Humans, Hypersensitivity/prevention & control, Male, Pyroglyphidae/immunology",
author = "{de Bot}, {Cindy M A} and Heleen Moed and Berger, {Marjolein Y} and Esther R{\"o}der and Hop, {Wim C J} and {de Groot}, Hans and {de Jongste}, {Johan C} and {van Wijk}, {Roy Gerth} and Bindels, {Patrick J E} and {van der Wouden}, {Johannes C}",
note = "{\circledC} 2011 John Wiley & Sons A/S.",
year = "2012",
month = "3",
doi = "10.1111/j.1399-3038.2011.01219.x",
language = "English",
volume = "23",
pages = "150--8",
journal = "Pediatric and Allergy Immunology",
issn = "0905-6157",
publisher = "Blackwell Munksgaard",
number = "2",

}

de Bot, CMA, Moed, H, Berger, MY, Röder, E, Hop, WCJ, de Groot, H, de Jongste, JC, van Wijk, RG, Bindels, PJE & van der Wouden, JC 2012, 'Sublingual immunotherapy not effective in house dust mite-allergic children in primary care' Pediatric and Allergy Immunology, vol. 23, no. 2, pp. 150-8. https://doi.org/10.1111/j.1399-3038.2011.01219.x

Sublingual immunotherapy not effective in house dust mite-allergic children in primary care. / de Bot, Cindy M A; Moed, Heleen; Berger, Marjolein Y; Röder, Esther; Hop, Wim C J; de Groot, Hans; de Jongste, Johan C; van Wijk, Roy Gerth; Bindels, Patrick J E; van der Wouden, Johannes C.

In: Pediatric and Allergy Immunology, Vol. 23, No. 2, 03.2012, p. 150-8.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Sublingual immunotherapy not effective in house dust mite-allergic children in primary care

AU - de Bot, Cindy M A

AU - Moed, Heleen

AU - Berger, Marjolein Y

AU - Röder, Esther

AU - Hop, Wim C J

AU - de Groot, Hans

AU - de Jongste, Johan C

AU - van Wijk, Roy Gerth

AU - Bindels, Patrick J E

AU - van der Wouden, Johannes C

N1 - © 2011 John Wiley & Sons A/S.

PY - 2012/3

Y1 - 2012/3

N2 - BACKGROUND: Sublingual immunotherapy (SLIT) as a therapy for the treatment of allergic rhinitis in children might be acceptable as an alternative for subcutaneous immunotherapy. However, the efficacy of SLIT with house dust mite extract is not well established.OBJECTIVE: To investigate whether SLIT in house dust mite-allergic children recruited in primary care is effective and safe.METHODS: Children aged 6-18 years (n = 251) recruited in primary care with a house dust mite-induced allergic rhinitis received either SLIT or placebo for 2 years. Symptoms and medication use were assessed throughout the study. Primary outcome parameter was the mean total nose symptom score (scales 0-12) during the autumn of the second treatment year. Safety was assessed by recording any adverse event.RESULTS: Overall, the mean nose symptom score ± s.d. after 2 years of treatment showed no significant effect of SLIT (symptom score intervention group 2.26 ± 1.84 vs. placebo group, 2.02 ± 1.67; p = 0.08). There were no significant differences in secondary outcomes, nor in subgroup analyses. The number of patients reporting adverse events was comparable between both groups.CONCLUSIONS: Sublingual immunotherapy with house dust mite allergen was not better than placebo in reducing rhinitis symptoms in house dust mite-allergic children in primary care. SLIT as administered in this study can be considered safe.

AB - BACKGROUND: Sublingual immunotherapy (SLIT) as a therapy for the treatment of allergic rhinitis in children might be acceptable as an alternative for subcutaneous immunotherapy. However, the efficacy of SLIT with house dust mite extract is not well established.OBJECTIVE: To investigate whether SLIT in house dust mite-allergic children recruited in primary care is effective and safe.METHODS: Children aged 6-18 years (n = 251) recruited in primary care with a house dust mite-induced allergic rhinitis received either SLIT or placebo for 2 years. Symptoms and medication use were assessed throughout the study. Primary outcome parameter was the mean total nose symptom score (scales 0-12) during the autumn of the second treatment year. Safety was assessed by recording any adverse event.RESULTS: Overall, the mean nose symptom score ± s.d. after 2 years of treatment showed no significant effect of SLIT (symptom score intervention group 2.26 ± 1.84 vs. placebo group, 2.02 ± 1.67; p = 0.08). There were no significant differences in secondary outcomes, nor in subgroup analyses. The number of patients reporting adverse events was comparable between both groups.CONCLUSIONS: Sublingual immunotherapy with house dust mite allergen was not better than placebo in reducing rhinitis symptoms in house dust mite-allergic children in primary care. SLIT as administered in this study can be considered safe.

KW - Administration, Sublingual

KW - Adolescent

KW - Animals

KW - Antigens, Dermatophagoides/administration & dosage

KW - Child

KW - Desensitization, Immunologic/methods

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Hypersensitivity/prevention & control

KW - Male

KW - Pyroglyphidae/immunology

U2 - 10.1111/j.1399-3038.2011.01219.x

DO - 10.1111/j.1399-3038.2011.01219.x

M3 - Article

VL - 23

SP - 150

EP - 158

JO - Pediatric and Allergy Immunology

JF - Pediatric and Allergy Immunology

SN - 0905-6157

IS - 2

ER -